BRAF突变非小细胞肺癌患者的临床结局:法国胸科协作组Biomarkers France研究结果
该研究基于法国胸科协作组Biomarkers France前瞻性队列,采用病例对照设计,将83例IV期BRAF突变NSCLC与166例EGFR、KRAS、HER2、BRAF、PIK3CA及ALK均野生型的对照按性别、诊断年龄和吸烟状态1:2匹配。结果显示两组一线和二线无进展生存期及疾病控制率均无显著差异,BRAF突变不是总生存的预后因素,且BRAF V600E与非V600E亚组与对照相比结局均无显著差异。
要点
- BRAF突变NSCLC一线及二线无进展生存期与野生型对照无显著差异。
- BRAF突变不是非小细胞肺癌的强预后因素。
- BRAF V600E与非V600E患者结局与对照相比均无显著差异。
核心结论
- BRAF突变不是非小细胞肺癌的强预后因素。
- 尽管以紫杉类为基础的治疗在一线显示最差的无进展生存期,但没有任何化疗方案与预后相关。
研究设计与样本
- 法国胸科协作组(IFCT)Biomarkers France研究是一项全国性前瞻性队列研究,旨在描述所有连续纳入的非小细胞肺癌患者(N=17,664)的分子特征和临床结局。
- 本研究利用该数据集建立病例对照分析:病例为IV期BRAF突变(BRAF-MT)NSCLC患者,对照为EGFR、KRAS、HER2、BRAF、PIK3CA和ALK均野生型的NSCLC患者。
- 每例病例按性别、诊断年龄和吸烟状态与随机选取的2例对照匹配。
主要发现
- 共83例BRAF突变病例(66.3%为V600E)与166例对照匹配。
- 5例病例在一线接受酪氨酸激酶抑制剂治疗,16例在二线接受酪氨酸激酶抑制剂治疗,其余均接受标准化疗。
- 两组一线和二线无进展生存期(PFS)以及疾病控制率均无显著差异,BRAF突变未发现是总生存的预后因素。
- 在BRAF-MT患者中,一线或二线所用治疗类型与对照相比结局无显著差异,BRAF V600E或非V600E与对照相比结局也无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with stage IV non-small-cell lung cancer (NSCLC) and BRAF V600 mutations may benefit from targeted therapies. Chemotherapy outcomes are little known in this population. METHODS: The French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study was a national prospective cohort study aiming to describe the molecular characteristics and clinical outcome of all consecutive NSCLC patients (N = 17,664) screened for molecular alterations. We used this data set to set up a case-control analysis. Cases had stage IV BRAF-mutated (BRAF-MT) NSCLC, whereas controls had NSCLC that was wild-type for EGFR, KRAS, HER2, BRAF, PIK3CA and ALK. Each case was matched for sex, age at diagnosis and smoking status to two controls randomly selected. RESULTS: Overall, 83 cases with BRAF mutant disease (66.3% V600E) were matched to 166 controls. Five cases received tyrosine kinase inhibition in the first-line and 16 in the second-line. All others were treated with standard chemotherapy. There was no significant difference in first-line and second-line progression-free survival (PFS) between the groups, as well as in the disease control rate, BRAF mutation was not found to be prognostic of overall survival. We found no significant difference in outcome between the treatment types used in first-line or second-line in patients with BRAF-MT disease compared with controls nor between BRAF V600E or non-V600E compared with controls. CONCLUSIONS: BRAF mutation is not a strong prognostic factor in NSCLC. Although taxan-based therapy shows poorest PFS in first-line, no chemotherapy regimen was associated with prognosis.
引用
- Couraud S, Barlesi F, Fontaine-Deraluelle C, et al. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. Eur J Cancer. 2019. PMID: 31181537. doi:10.1016/j.ejca.2019.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。